Is the FDA Pausing More Cancer Trials? It's Hard to Tell

Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.

Related Keywords

United States ,Boston ,Massachusetts ,Washington ,American ,Matthewe Brown ,Joshua Sharfstein ,Derek Scholes ,Nelson Mullins ,Julier Gralow ,Johns Hopkins Bloomberg School Of Public Health ,American Society Of Clinical Oncology ,Drug Administration ,Biotechnology Industry Organization ,National Institutes Of Health ,American Society ,Can Trigger ,Innate Pharma ,Care Numbers ,Wall Street Journal ,Information Act ,National Institutes ,Medscape Medical ,Transparency But ,Johns Hopkins Bloomberg School ,Public Health ,Lira Loss ,Lung Cancer ,Ung Carcinoma ,Ancer Of The Lung ,Biologic Therapy ,Iologics ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Healthcare Technology ,Medical Technology ,Genomics Genomic Medicine ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Skin Cancer ,Alignant Skin Neoplasm ,Small Cell Lung Cancer ,